Eisai Newswire

Comprehensive Real-Time News Feed for Eisai.

Results 1 - 20 of 58 in Eisai

  1. Eisai, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances...Read the original story

    Tuesday Mar 24 | PR-inside.com

    Report Description MarketLines' Eisai, Inc. Mergers & Acquisitions , Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions , divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Eisai, Inc. since January 2007. Report Scope * Provides intelligence on Eisai, Inc.'s M&A, strategic partnerships and alliances, capital raising and private equity transactions.

    Comment?

  2. Arena Pharmaceuticals, Inc. Provides Corporate Update And Reports...Read the original story

    Monday Mar 2 | BioSpace

    ... quarter, despite an overall market decline of 4%. . These results reflect the impact of a new savings card launched by Eisai in early 2015 that enables eligible patients without commercial coverage for BELVIQ to pay no more than Announced top-line ...

    Comment?

  3. Eisai Launches Anticancer Agent Lenvima in the United StatesRead the original story

    Monday Mar 2 | Sys-Con Media

    First Country in the World to Gain Access to New Treatment Option TOKYO, Mar 2, 2015 - - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. The United States is the first country in the world where the agent has been launched.

    Comment?

  4. LENVIMA(TM) (lenvatinib) Now Available Through Two Specialty Pharmacies, Accredo and Biologics, Inc.Read the original story

    Friday Feb 27 | Freshnews

    Eisai Inc. announced today that LENVIMA , a receptor tyrosine kinase inhibitor, is now available through two specialty pharmacies, Accredo and Biologics, Inc. LENVIMA is indicated for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer . LENVIMA, an oral capsule taken once daily, was approved by the U.S. Food and Drug Administration on February 13, 2015, following a Priority Review by the FDA.

    Comment?

  5. Eisai Inc. Release: Topline Results Of Phase 3 Trial Show Eribulin...Read the original story

    Feb 24, 2015 | BioSpace

    Eisai Inc. Release: Topline Results Of Phase 3 Trial Show Eribulin Mesylate Injection Meets Primary Endpoint Of Overall Survival In Advanced Soft Tissue Sarcoma /PRNewswire/ -- Eisai Inc. today announced that eribulin met the primary endpoint in its Phase 3 trial , demonstrating a statistically significant improvement in overall survival in patients with advanced soft tissue sarcomas versus the comparator treatment dacarbazine. Eisai plans to present these data at an upcoming medical meeting.

    Comment?

  6. Eisai Inc. Launches BELVIQ?? VOICES, an Online Community Of Personal...Read the original story

    Feb 18, 2015 | BioSpace

    Eisai Inc. Launches BELVIQA VOICES, an Online Community Of Personal Weight Loss Stories, Featuring Real Life Experiences With BELVIQA CIV /PRNewswire/ -- Eisai Inc. today announced the launch of BELVIQ VOICES, an online community featuring real life weight loss journeys of patients living with obesity. Meant to inspire and encourage honest, open conversation with physicians, BELVIQ VOICES has as its centerpiece heartfelt stories of patients who have struggled with weight loss for many years.

    Comment?

  7. Eisai Receives Approval for Antiepileptic Drug Banzel (rufinamide) As ...Read the original story w/Photo

    Feb 15, 2015 | Drugs.com

    February 16, 2015 -- Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval of an additional pediatric indication for Eisai's antiepileptic drug Banzel from the U.S. Food and Drug Administration . Through this approval, Banzel, which had been approved for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children four years older and adults, is now additionally approved for the same indication in pediatric patients from one to less than four years of age in the United States.

    Comment?

  8. FDA Approves Eisai's Thyroid Cancer DrugRead the original story w/Photo

    Feb 15, 2015 | Medical Daily

    The U.S. Food and Drug Administration said it approved Japan's Eisai Co Ltd's drug to treat the most common form of thyroid cancer more than two months ahead of the review date. The drug, Lenvima, was cleared for use in patients with progressive, differentiated thyroid cancer who have not adequately responded to radioactive iodine therapy, the agency said on Friday.

    Comment?

  9. Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTCRead the original story w/Photo

    Feb 13, 2015 | Medical News

    Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer . LENVIMA was approved following a priority review by the FDA, which is designated for drugs the FDA believes have the potential to provide a significant improvement in the treatment of a serious condition.

    Comment?

  10. Multimedia Assets Now Available: FDA Approves Eisai's LENVIMA(TM)...Read the original story

    Feb 13, 2015 | Freshnews

    Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer . LENVIMA was approved following a priority review by the FDA, which is designated for drugs the FDA believes have the potential to provide a significant improvement in the treatment of a serious condition.

    Comment?

  11. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Feb 13, 2015 | Business Wire

    )--Biologics, Inc. an integrated oncology services company, is pleased to announce that Eisai Inc. has selected Biologics to be a specialty pharmacy provider within its li... )--Research and Markets (http://www ...

    Comment?

  12. FDA Approves Eisai's LENVIMA(TM) (lenvatinib) for the Treatment...Read the original story

    Feb 13, 2015 | Freshnews

    Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer . LENVIMA was approved following a priority review by the FDA, which is designated for drugs the FDA believes have the potential to provide a significant improvement in the treatment of a serious condition.

    Comment?

  13. Lenvima Gets FDA Approval to Treat Thyroid CancerRead the original story

    Feb 13, 2015 | Kansas City InfoZine

    ... suppression of the production of thyroid-stimulating hormone. Lenvima is marketed by Woodcliff Lake, New Jersey-based Eisai Inc.

    Comment?

  14. REFILE-UPDATE 1-FDA approves Eisai's thyroid cancer drugRead the original story

    Feb 13, 2015 | Reuters

    The U.S. Food and Drug Administration said it approved Japan's Eisai Co Ltd's drug to treat the most common form of thyroid cancer more than two months ahead of the review date. The drug, Lenvima, was cleared for use in patients with progressive, differentiated thyroid cancer who have not adequately responded to radioactive iodine therapy, the agency said on Friday.

    Comment?

  15. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Feb 13, 2015 | Business Wire

    ... (CLICE) and its sister comp... )--Biologics, Inc. an integrated oncology services company, is pleased to announce that Eisai Inc. has selected Biologics to be a specialty pharmacy provider within its li... )--Research and Markets ...

    Comment?

  16. Lenvimaa (Lenvatinib) Approved for Radioactive Iodine-Refractory...Read the original story

    Feb 13, 2015 | Freshnews

    Biologics, Inc. an integrated oncology services company, is pleased to announce that Eisai Inc. has selected Biologics to be a specialty pharmacy provider within its limited distribution network for Lenvima . Lenvima was approved by the U.S. Food and Drug Administration on February 13, 2015 for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy.

    Comment?

  17. Eisai Announces FDA Approval of BANZELA (rufinamide) for Adjunctive...Read the original story

    Feb 13, 2015 | Freshnews

    Eisai Inc. announced today that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for BANZEL as an adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients from one to four years of age. BANZEL was first approved by the FDA in November 2008, for the adjunctive treatment of seizures associated with LGS in children ages four years and older and adults.

    Comment?

  18. Pivotal Phase 3 Trial of Investigational Agent Lenvatinib in...Read the original story

    Feb 12, 2015 | Sys-Con Media

    The article, "Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer," reports the results of the multicenter, randomized, double-blind, placebo-controlled Phase 3 study that evaluated lenvatinib versus placebo in 392 patients with RAI-refractory DTC who had progressed within the prior 12 months. "For patients who undergo surgery and radioactive iodine treatment, but still progress to RAI-refractory DTC, the prognosis is poor and there are currently few effective therapies available," said Professor , Ph.D., President, Oncology Product Creation Unit at Eisai Inc. "As a human health care company, Eisai is committed to quality research and development to discover and deliver needed treatment options to patients."

    Comment?

  19. Eisai Inc. Release: Pivotal Phase 3 Trial of Investigational Agent...Read the original story

    Feb 11, 2015 | BioSpace

    Eisai Inc. Release: Pivotal Phase 3 Trial of Investigational Agent Lenvatinib In Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published In New England Journal Of Medicine hyroid) trial evaluating the use of investigational agent lenvatinib in the treatment of progressive, radioactive iodine-refractory differentiated thyroid cancer were published online today in the New England Journal of Medicine . The article, "Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer," reports the results of the multicenter, randomized, double-blind, placebo-controlled Phase 3 study that evaluated lenvatinib versus placebo in 392 patients with RAI-refractory DTC who had progressed within the prior 12 months.

    Comment?

  20. Eisai Inc. Launches New Savings Card To Increase Access And...Read the original story w/Photo

    Jan 19, 2015 | BioSpace

    /PRNewswire/ -- Eisai Inc. today announced the launch of a new savings card for BELVIQ A (lorcaserin HCl) CIV, the most prescribed branded FDA-approved prescription drug therapy for chronic weight management.** The new savings card enables eligible ...

    Comment?